RecruitingEarly Phase 1NCT03746535
Cardiovascular Disease Risk in Women With Endometriosis
Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Women With Endometriosis
Sponsor
Yale University
Enrollment
40 participants
Start Date
Jul 1, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years
Inclusion Criteria2
- Young women between the ages of 18 and 45 years (Controls);
- Young women between the ages of 18 and 45 years with endometriosis.
Exclusion Criteria4
- Subjects who smoke
- Subjects who have diabetes,
- Subjects with sleep apnea or BP>140/90 will be excluded.
- Women with endometriosis and severe acute pain requiring immediate treatment will be excluded.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGElagolix
Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03746535
Related Trials
A Randomized Controlled Trial of a Nutritional Intervention for Endometriosis
NCT070900961 location
Stanford Program to Accelerate Robotic Children's Surgery
NCT066716391 location
The Good Pain Consultation in Endometriosis.
NCT072056141 location
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT045677713 locations
Nutritional Intervention for Endometriosis
NCT051752481 location